Clinical Trial Update: An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

An extension study evaluating the efficacy and safety of Fingolimod (Gilenya) in relapsing multiple sclerosis has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2013-09-04